Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyDalantercept
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Dalantercept
- Accession Number
- DB14988
- Type
- Biotech
- Groups
- Investigational
- Description
Dalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).
- Synonyms
- Not Available
- External IDs
- ACE-041
- Categories
- Activin Receptors
- Amino Acids, Peptides, and Proteins
- Blood Proteins
- Enzymes
- Enzymes and Coenzymes
- Globulins
- Immunoglobulin Constant Regions
- Immunoglobulin Fragments
- Immunoglobulins
- Immunoproteins
- Membrane Proteins
- Peptide Fragments
- Peptides
- Phosphotransferases
- Phosphotransferases (Alcohol Group Acceptor)
- Protein Kinases
- Protein-Serine-Threonine Kinases
- Proteins
- Receptors, Cell Surface
- Receptors, Cytokine
- Receptors, Growth Factor
- Receptors, Immunologic
- Receptors, Peptide
- Receptors, Transforming Growth Factor beta
- Recombinant Proteins
- Serum Globulins
- Transferases
- UNII
- EGC16R10V0
- CAS number
- 1186210-24-1
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Dalantercept. Abituzumab The risk or severity of adverse effects can be increased when Abituzumab is combined with Dalantercept. Abrilumab The risk or severity of adverse effects can be increased when Dalantercept is combined with Abrilumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Dalantercept. Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Dalantercept. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Dalantercept. Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Dalantercept. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dalantercept. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Dalantercept. Amatuximab The risk or severity of adverse effects can be increased when Amatuximab is combined with Dalantercept. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- Wikipedia
- ALK_inhibitor
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Advanced Solid Tumors / Multiple Myeloma (MM) 1 1, 2 Completed Treatment Advanced Adult Hepatocellular Carcinoma 1 2 Active Not Recruiting Treatment Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma 1 2 Completed Treatment Advanced Renal Cell Carcinoma 1 2 Completed Treatment Endometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Mixed Adenocarcinoma / Endometrial Mucinous Adenocarcinoma / Endometrial Serous Adenocarcinoma / Endometrial Squamous Cell Carcinoma / Endometrial Transitional Cell Carcinoma / Endometrial Undifferentiated Carcinoma / Recurrent Uterine Corpus Carcinoma 1 2 Completed Treatment Squamous Cell Carcinoma of the Head and Neck (SCCHN) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Taxonomy
- Classification
- Not classified
Drug created on May 20, 2019 08:39 / Updated on November 02, 2019 03:28